Seres Therapeutics (MCRB) said Thursday it received a $50 million installment related to the sale of its VOWST business to Societe des Produits Nestle.
The company said in September that it received $175 million in gross proceeds and expects to receive two installment payments.
Seres said it expects the next installment of $25 million in July.
Current cash reserves and anticipated future deal payments are anticipated to extend the company's cash runway into Q1 2026, Seres added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.